Highlights from the 6th Annual CCA Summit

Several medical advances made in the treatment of cholangiocarcinoma (CCA) were presented at the 2024 CCA Summit, including updates in chemotherapy, targeted therapies, targeted protein degradation, antibody–drug conjugates, and liver-directed therapies.

At the 2024 CCA Summit, presenters debated on whether to use surgery, transplant, or hepatic arterial pump for localized multifocal biliary tract cancer.

At the 2024 CCA Summit, Joshua Kuban, MD, FSIR, discussed interventional radiology therapies for the treatment of patients with cholangiocarcinoma, and Eugene Koay, MD, PhD, discussed stereotactic body radiation therapy.

At the 2024 CCA Summit, Laura Goff, MD, MSCI, MMHC, and Jingquan Jia, MD, PhD, debated the pros and cons of circulating tumor DNA monitoring in biliary tract cancer.

At the 2024 CCA Summit, Iwan Paolucci, PhD, presented on the topic “Innovations of Artificial Intelligence in Cholangiocarcinoma” in which he described the many applications of artificial intelligence in oncology, including drug discovery, diagnosis, prognosis, and treatment.

Several surgical approaches for the treatment of cholangiocarcinoma were presented at the 2024 CCA Summit, including minimally invasive resection, the comparison of neoadjuvant, perioperative, and adjuvant treatments, and how to integrate adjuncts into surgery.

At the 2024 CCA Summit, Maria A. Hawkins, MD, FRCR, MRCP, and Jordan Berlin, MD, debated on the role for consolidative radiotherapy in patients with locally advanced cholangiocarcinoma.

Numerous informative and engaging posters were showcased at the 2024 CCA Summit. There were 3 posters presented highlighting clinical trials in immunotherapy...